ODAC gives thumbs down to single-arm trial of two-drug combination for multiple myeloma

It's not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.